S Hou1, P Du2, P Wang3, C Wang4, P Liu5, H Liu6. 1. Department of Pharmacology, Yidu Central Hospital of Weifang Affiliated to Weifang Medical University, Weifang, 261000, Shandong, China. 2. Department of Plastic Surgery, Yidu Central Hospital of Weifang Affiliated to Weifang Medical University, Weifang, 261000, Shandong, China. 3. Department of Pain Treatment, Qingzhou Hospital of Traditional Chinese Medicine, Weifang, 261000, Shandong, China. 4. Department of Reproductive Center, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, Sichuan, China. 5. Department of Burn and Plastic Surgery, Qilu Hospital Affiliated to Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China. liupei_peiliu@126.com. 6. Department of General Surgery, Qilu Hospital Affiliated to Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China. liuhongda188@163.com.
Abstract
BACKGROUND: Ovarian cancer is the most lethal gynecologic malignancy worldwide with surgery as the only curative treatment. Long-term overall survival (OS) of ovarian cancer is far from satisfactory, even though significant improvement has been made in post-operative chemotherapy. One of the most important death cause is the chemoresistance due to consecutive chemotherapy. Therefore, understanding the molecular mechanisms involved in ovarian cancer development and identification of novel therapeutic targets are urgently required. METHODS: Immunohistochemical (IHC) staining was used to explore the expression pattern of mitogen-activated protein kinase (MAPK)-interacting kinase 1 (MNK1) in tumor tissues from 138 epithelial ovarian cancer (EOC) patients. Clinicopathological data were subjected to Kaplan-Meier survival and Cox multivariate analyses to evaluate the prognostic value of MNK1 in EOC. Overexpression and silencing procedures were performed on OVCAR-5 cells to investigate the mechanisms of MNK1 in regulating EOC development. The anti-tumor effects of CGP57380, a specific MNK inhibitor, were examined by cell viability assay. RESULTS: Higher MNK1 expression showed significant relationship with advanced FIGO stage and positive lymph node metastasis of EOC. Univariate and multivariate analyses revealed that MNK1 was an independent prognostic factor for OS of EOC patients. In vitro study demonstrated that MNK1 can promote cell proliferation through regulating the phosphorylation level of eukaryotic initiation factor 4E. In addition, inhibition of MNK1 by CGP57380 significantly down-regulated the OVCAR-5 cell viability. CONCLUSION: High MNK1 expression in EOC tissues indicates poor clinical outcomes, and MNK1 can act as a potential target for novel chemotherapy development towards EOC.
BACKGROUND:Ovarian cancer is the most lethal gynecologic malignancy worldwide with surgery as the only curative treatment. Long-term overall survival (OS) of ovarian cancer is far from satisfactory, even though significant improvement has been made in post-operative chemotherapy. One of the most important death cause is the chemoresistance due to consecutive chemotherapy. Therefore, understanding the molecular mechanisms involved in ovarian cancer development and identification of novel therapeutic targets are urgently required. METHODS: Immunohistochemical (IHC) staining was used to explore the expression pattern of mitogen-activated protein kinase (MAPK)-interacting kinase 1 (MNK1) in tumor tissues from 138 epithelial ovarian cancer (EOC) patients. Clinicopathological data were subjected to Kaplan-Meier survival and Cox multivariate analyses to evaluate the prognostic value of MNK1 in EOC. Overexpression and silencing procedures were performed on OVCAR-5 cells to investigate the mechanisms of MNK1 in regulating EOC development. The anti-tumor effects of CGP57380, a specific MNK inhibitor, were examined by cell viability assay. RESULTS: Higher MNK1 expression showed significant relationship with advanced FIGO stage and positive lymph node metastasis of EOC. Univariate and multivariate analyses revealed that MNK1 was an independent prognostic factor for OS of EOC patients. In vitro study demonstrated that MNK1 can promote cell proliferation through regulating the phosphorylation level of eukaryotic initiation factor 4E. In addition, inhibition of MNK1 by CGP57380 significantly down-regulated the OVCAR-5 cell viability. CONCLUSION: High MNK1 expression in EOC tissues indicates poor clinical outcomes, and MNK1 can act as a potential target for novel chemotherapy development towards EOC.
Authors: Luc Furic; Liwei Rong; Ola Larsson; Ismaël Hervé Koumakpayi; Kaori Yoshida; Andrea Brueschke; Emmanuel Petroulakis; Nathaniel Robichaud; Michael Pollak; Louis A Gaboury; Pier Paolo Pandolfi; Fred Saad; Nahum Sonenberg Journal: Proc Natl Acad Sci U S A Date: 2010-08-02 Impact factor: 11.205
Authors: Ashley Sinclair Felix; Roslyn A Stone; Robert Bowser; Mamatha Chivukula; Robert P Edwards; Joel L Weissfeld; Faina Linkov Journal: Int J Gynecol Cancer Date: 2011-07 Impact factor: 3.437
Authors: Hans-Guido Wendel; Ricardo L A Silva; Abba Malina; John R Mills; Hong Zhu; Takeshi Ueda; Rie Watanabe-Fukunaga; Rikiro Fukunaga; Julie Teruya-Feldstein; Jerry Pelletier; Scott W Lowe Journal: Genes Dev Date: 2007-11-30 Impact factor: 11.361
Authors: Celia Pinto-Díez; Eva M García-Recio; M Isabel Pérez-Morgado; Marta García-Hernández; Lara Sanz-Criado; Silvia Sacristán; M Val Toledo-Lobo; Belén Pérez-Mies; Isabel Esteban-Rodríguez; Alejandro Pascual; Mercedes Garcia-Villanueva; Noelia Martínez-Jañez; Víctor M González; M Elena Martín Journal: Oncotarget Date: 2018-02-05